Prof. Xia He 何侠
Chief Physician, Professor
Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for malignant tumors, with a focus on precise radiotherapy and comprehensive treatment for head and neck cancers, particularly nasopharyngeal carcinoma.
Dr. He is Professor and Chief Physician at Jiangsu Cancer Hospital, serving as Vice President. Dr. He holds a doctorate in oncology and leads the radiation oncology department. Training includes visiting scholar roles at OHSU and short-term training at Harvard Medical School, MD Anderson Cancer Center, and Karolinska Institute. Dr. He serves on editorial boards for several medical journals and has translated or edited multiple textbooks on radiation oncology.
Professional roles
- Chair, Jiangsu Medical Association Branch of Radiation Oncology
- Chair, China Anti-Cancer Association Committee on Radiation Medicine
- Standing Committee Member, Chinese Society of Clinical Oncology (CSCO) Committee on Radiation Oncology
- Member, Chinese Medical Association Branch of Radiation Oncology
Name order: in Chinese the family name comes first (He Xia). Papers usually list the name as Xia He or He X.
Selected publications
206 papers on PubMed matched by name and affiliation; 94 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Transl Radiat Oncol, 2027 (senior author): Validation and refinement of the N classification for nasopharyngeal carcinoma based on the 9th version AJCC/UICC TNM staging system in non-endemic regions of China: a multicenter cohort study. PubMed 42756520
- Front Oncol, 2026 (senior author): Case Report: Low-dose radiotherapy as part of multimodal salvage therapy for immunotherapy-resistant SMARCA4-deficient non-small cell lung cancer. PubMed 42898113
- Anticancer Drugs, 2026 (senior author): APG-1252 enhances the anticancer role of paclitaxel in non-small-cell lung cancer cells by suppressing the extracellular regulated protein kinases/myeloid cell leukemia 1 pathway. PubMed 41608859
- Front Biosci (Landmark Ed), 2026 (senior author): PCSK9 as a Key Gene of Metastasis in Lung Adenocarcinoma: A Multi-omics and Experimental Validation Study. PubMed 42689992
- Signal Transduct Target Ther, 2026 (senior author): C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy. PubMed 42575887
- Radiat Oncol, 2026 (senior author): Multi-regional radiomics based on planning CT and information complementarity between GTVp and GTVn: an explainable model for predicting 5-year recurrence risk in HPV-positive oropharyngeal cancer. PubMed 42421141
- Cancer Med, 2026 (senior author): Watch and Wait Strategy for Locally Advanced Rectal Cancer: Update From Results of Recent Clinical Trials. PubMed 42432833
- Radiother Oncol, 2026 (senior author): Capturing "source" and "evolution": A 5-year recurrence risk prediction model for nasopharyngeal carcinoma based on integrated radiomic spatial heterogeneity of primary tumor and lymph nodes. PubMed 42061756
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion